Your donation may qualify for a matching gift. Check your employee giving portal for eligibility and details.
Every woman deserves the best possible information to guide her breast cancer treatment. Delphi Diagnostics’ Endocrine Activity Index® (EAI) aims to fill a critical gap in today’s testing by helping doctors better understand how a patient’s tumor may respond to hormone therapy. Your support can help expand patient access, provide financial assistance to women who cannot afford the test, and accelerate the path toward insurance coverage. Together, we can help bring more personalized treatment decisions within reach and move closer to a future where every woman receives the right treatment at the right time. Donate today to help turn scientific innovation into meaningful impact for women with breast cancer.
For more than 20 years, genomic tests such as Oncotype DX® have helped doctors make better treatment decisions for women with early-stage breast cancer. By helping identify women who are likely (or unlikely) to benefit from chemotherapy, these tests have spared many patients from unnecessary treatment and its side effects.
But there is still a major piece of the puzzle missing.
For roughly 70% of breast cancer patients, hormone therapy is an important part of treatment. Yet the tests doctors routinely use today cannot tell them how likely a particular patient is to benefit from hormone therapy – or whether she may need a different approach.
That means doctors are often making one of the most important decisions in a woman’s cancer journey without having all the information they need.
Delphi Diagnostics developed the Endocrine Activity Index® (EAI) to help close this gap. EAI is designed to provide doctors with new information about how a patient’s tumor is responding to hormone signals – information that isn’t captured by today’s standard genomic tests.
The promise is simple: help doctors choose the treatment most likely to work for each individual woman, from the start.
Better information can mean better treatment decisions, fewer unnecessary treatments and side effects, and a greater chance that patients receive the right therapy at the right time.
Funding will help bring the Endocrine Activity Index® (EAI) to more patients sooner, while accelerating the path toward Medicare reimbursement. Once covered by Medicare, EAI could become accessible to women who may otherwise be unable to afford this important test.
Funding will also support the continued development and improvement of EAI, helping build the clinical evidence needed for its adoption into medical guidelines and, ultimately, its potential to become a new standard of care for women with breast cancer.
Funds will be used to launch a Patient Assistance Program to help women who cannot afford the test access potentially valuable insights to guide their cancer treatment. By removing financial barriers, we can help ensure that cost does not stand in the way of more informed treatment decisions.
Delphi Diagnostics has already built a strong foundation for bringing the Endocrine Activity Index® (EAI) to women with breast cancer.
The technology was originally developed at MD Anderson Cancer Center and has since been evaluated in 10 clinical trials involving more than 8,000 patients, with 16 peer-reviewed publications supporting the science. Delphi has also launched an Early Access Program, with 100% of participating physicians continuing to use the test—an encouraging signal of its value in clinical practice.
The next step is turning this strong clinical foundation into broad patient access.
New funding will help Delphi expand access to EAI, support the evidence and work needed to secure Medicare and private insurance coverage, and continue improving and advancing the technology. In other words, the funding will help move EAI from a promising, clinically validated test to one that can reach many more women who could benefit from it.
Importantly, this funding will also help de-risk the key milestones needed for commercialization. Demonstrating continued clinical progress, growing patient access, and advancing reimbursement will give strategic investors and philanthropic partners greater confidence to provide the additional capital needed to scale the program.
Without funding to bridge the “Valley of Death,” a clinically validated breakthrough like EAI could remain on the sidelines—delaying access for the hundreds of thousands of women who could benefit from more personalized breast cancer treatment.
Without better tools, doctors must continue relying on tests that do not provide the full picture of how an individual patient is likely to respond to hormone therapy. This can leave women at risk of unnecessary treatment, avoidable side effects, or missed opportunities to choose a therapy better suited to their individual cancer.
Bridging this funding gap is therefore about more than advancing a promising technology. It is about shortening the time between scientific discovery and the moment a patient can actually benefit from it—and accelerating the move toward a more personalized standard of breast cancer care.
Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer
Founder & Cheif Executive Officer
Winz Casagrande, Dr. jur., lic. oec. HSG, ICD.D, is the Founder, CEO, and Chair of Delphi Diagnostics Inc., where she has led the company’s commercialization from inception through multiple capital raises. An accomplished entrepreneur, executive, and board director, she brings extensive international experience in corporate governance, strategic leadership, team building, and raising capital for innovative, mission-driven enterprises. Her previous leadership roles include Global Head of Market and Product Strategy at Royal Bank of Canada Dexia and National Director of Real Estate at Ernst & Young Canada. She currently serves on the board of Park Lawn Corporation, where she contributes to governance, audit, and compensation committees, and chairs RESCo Lease. Winz holds a doctorate in law from the University of Hannover, a degree in economics from the University of St. Gallen, and the ICD.D designation from the Institute of Corporate Directors. As a breast cancer survivor, she brings a deeply personal commitment to advancing more personalized cancer care.
Chief Financial Officer
Eric Lindquist is a proven pharmaceutical and diagnostics executive and board member with decades of leadership experience. Most recently, he served as CEO of InnoSIGN, a U.S.- and Netherlands-based techbio company, where he led a strategic pivot and completed two financing rounds.
Prior to InnoSIGN, he was Chief Business and Commercial Officer at Celcuity, where he led the acquisition of gedatolisib and helped advance the program into Phase III breast cancer trials, which have reported highly positive outcomes for patients. Earlier in his career, he held senior leadership roles at Natera (NASDAQ: NTRA), where he helped launch Signatera, a personalized diagnostic built around each patient’s unique cancer signature, and previously helped establish Roche as a leader in companion diagnostics.
He earned a B.S. from the University of Minnesota and an MBA from Capella University.
Chief Commercial Officer
Chuck Morrison is a Global Business Development Executive with a successful track record negotiating and executing acquisitions, licensing deals, partnerships, and distribution deals. Chuck has 40 years of experience in Life science, Biotechnology and Diagnostics including 20 years of Corporate Business Development and 20 years of Operations Management.
Chuck currently is an independent consultant, providing business development and management experience to small biotech companies. Chuck was also a Board member for GenePOC Inc., a privately-owned company (part of the Debiopharm Group), a molecular diagnostic company. Chuck’s Board duties included being an active member of the Strategic Committee, the Audit Committee and was instrumental in the acquisition of GenePOC by Meridian Bioscience. Chuck is currently a Board member for XCR Diagnostics and Avisa Diagnostics.
Prior to consulting, Chuck was the Director of Business Development at PerkinElmer. He managed numerous acquisitions and technology deals which drove the strategic growth of PerkinElmer’s Life Science and Diagnostic businesses.
